This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ecancer
M

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients Undergoing MMUD HCT

By ecancer FEATURING Monzr Al Malki, Steven Devine
By ecancer FEATURING Monzr Al Malki, Steven Devine
25 views
July 24, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

09:04
ecancer

ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Mult…

Feat. X. Leleu
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
11:41
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Benefit of R Maintenance After 1L BR in M…

Feat. Y. Wang
View All

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
17:51
Indy Hematology Review

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Feat. H. Erba
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
19:21
SOHO Brazil 2024

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

Feat. J. Lancet
27:26
SOHO Brazil 2024

Where I Use Azacitidine and Venetoclax in AML: Present and Future

Feat. J. Lancet
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
08:47
Sarah Tasian

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

28:02
University of Colorado Division of Hematology

2024 Updates in AML

Feat. C. McMahon
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
14:32
Vanderbilt University Medical Center (VUMC)

Summary of Recent Updates in MDS

Feat. S. Ball
14:58
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger P…

Feat. C. McMahon
48:04
Icahn School of Medicine at Mount Sinai

Integrating Targeted Therapies in AML

Feat. H. Kantarjian
16:55
Moffitt Cancer Center

Making Sense of the New Classification Systems for MDS in 2024

Feat. R. Komrokji
16:28
Fred Hutchinson Cancer Center

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Feat. R. Cassaday
19:10
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian
27:28
UChicago Medicine

AML: Current Treatment Landscape and Key Recent Updates

Feat. A. Patel
23:15
Rush University Medical Center

Is Post-HSCT Maintenance the SOC for AML?

Feat. M. Levis